N-叔丁基烟酰胺 | 15828-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-叔丁基烟酰胺
• 英文名称: N-(tert-butyl)pyridine-3-carboxamide
• 英文别名: N-Tert-butylnicotinamide；N-tert-butylpyridine-3-carboxamide
• CAS: 15828-08-7
• 化学式: C₁₀H₁₄N₂O
• mdl: MFCD00707839
• 分子量: 178.234
• InChiKey: UKLIVFNPJKDBAX-UHFFFAOYSA-N

物化性质

• 沸点：
  351.7±15.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

SDS

N-叔丁基烟酰胺MSDS英文版

反应信息

• 作为反应物：
  描述：

  N-叔丁基烟酰胺 在 碘 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以75%的产率得到N-(tert-butyl)-4-iodopyridine-3-carboxamide
  参考文献：
  名称：

  Deprotonation of pyridine carboxamides using lithium magnesiates bases

  摘要：

  Regioselective deprotonation of N-methyl- and tert-butylpyridine carboxamides using lithium magnesiates bases was achieved at room temperature avoiding nucleophilic addition on the pyridine molecule and auto-condensation of the arylmetal intermediates on the amide group was described. The hydrogen-magnesium exchange was evidenced using H-1 NMR spectroscopy at room temperature and the reactivity of the lithium 2- 3- and 4-carboxamidopyridinylmagnesiates complexes towards electrophiles and in cross-coupling reactions was studied. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.01.064
• 作为产物：
  描述：

  氯化烟碱盐酸盐 以83%的产率得到N-叔丁基烟酰胺
  参考文献：
  名称：

  Amide derivative

  摘要：

  其中 Ar是可选择取代的苯基等；n为0、1或2； R1是氢原子、可选择取代的烷基等；R2和R3分别是可选择取代的烷基等； R4和R5分别是氢原子或可选择取代的烷基；R6是氢原子、羟基或烷基； 或其药学上可接受的盐对于治疗视网膜退行性疾病等疾病是有用的药物。

  公开号：

  US06384033B1

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150133407A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.

  本发明涉及公式I的化合物或其药用可接受的盐，以及它们的聚合物、溶剂化物、对映体、立体异构体和水合物。包含有效量的公式I化合物的药物组合物，以及用于治疗呼吸系统疾病的方法，可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病（COPD）、呼吸肌疾病和急性喉咙痛的疼痛。
• [EN] 6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS<br/>[FR] IMIDAZOPYRAZINES 6-SUBSTITUÉES POUR UTILISATION EN TANT QU'INHIBITEURS DE MPS-1 ET TKK DANS LE TRAITEMENT DE TROUBLES HYPERPROLIFÉRATIFS
  申请人：BAYER PHARMA AG

  公开号：WO2012080236A1

  公开（公告）日：2012-06-21

  The present invention relates to substituted imidazopyrazine compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）的取代咪唑吡嗪化合物，其中R1、R2、R3、R4和R5如权利要求中所定义，以及制备所述化合物的方法和中间体，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用时，用于治疗或预防过度增殖和/或血管生成紊乱的疾病。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS
  申请人：Kandula Mahesh

  公开号：US20150133475A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I化合物的有效量的药物组合物，以及用于牙周炎和类风湿关节炎治疗的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂的制剂。
• SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Smil David

  公开号：US20070293530A1

  公开（公告）日：2007-12-20

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I), and racemic and scalemic mixtures, diastereomers and enantiomers thereof: or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, prodrug or complex thereof, wherein Y, L, Z, W, M, R a , R b and R c are as defined in the specification.

  这项发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，该发明提供了符合式(I)的化合物，以及它们的外消旋和内消旋混合物、非对映体和对映体： 或其N-氧化物、水合物、溶剂合物、药学上可接受的盐、前药或其复合物，其中Y、L、Z、W、M、R a 、R b 和R c 如规范中所定义。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN
  申请人：Kandula Mahesh

  公开号：US20150152081A1

  公开（公告）日：2015-06-04

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain, generalized pain disorders, leukemia, cancer, chronic pain, chemotherapy induced pain, epilepsy, migraine, neuropathic pain, post herpetic neuralgia, neuralgia, pain, drug addiction, detoxification of drugs, Alzheimer's disease, multiple sclerosis, multiple sclerosis, restless legs syndrome (RLS), cluster headache, depression, fibromyalgia, amyotrophic lateral sclerosis (ALS), convulsions, partial seizures, mood-stabilizing agent and bipolar disorder.

  该发明涉及公式I的化合物或其药用可接受盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗严重疼痛的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗慢性疼痛、广泛性疼痛障碍、白血病、癌症、化疗引起的疼痛、癫痫、偏头痛、神经痛、带状疱疹后神经痛、神经痛、疼痛、药物成瘾、药物戒断、阿尔茨海默病、多发性硬化症、多发性硬化症、不宁腿综合征（RLS）、集束性头痛、抑郁症、纤维肌痛、肌萎缩侧索硬化症（ALS）、抽搐、部分性癫痫、情绪稳定剂和躁郁症的治疗。